Clinical effectiveness of decitabine in severe sickle cell disease
暂无分享,去创建一个
Y. Saunthararajah | D. Lavelle | R. Molokie | S. Saraf | J. Desimone | M. Gowhari | Seema Sidhwani | S. Vara | Michel Gowhari
[1] S. Pileri,et al. Rare expression of T-cell markers in classical Hodgkin's lymphoma , 2005, Modern Pathology.
[2] N. Mahmud,et al. Modification of hematopoietic stem cell fate by 5aza 2'deoxycytidine and trichostatin A. , 2004, Blood.
[3] R. Hoffman,et al. Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. , 2003, Blood.
[4] D. Lavelle,et al. Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia. , 2002, Blood.
[5] R. Hoffman,et al. 2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia. , 2000, Blood.
[6] J. Visvader,et al. Megakaryocytic differentiation induced in 416B myeloid cells by GATA-2 and GATA-3 transgenes or 5-azacytidine is tightly coupled to GATA-1 expression. , 1993, Blood.
[7] M. Koury,et al. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. , 1990, Science.
[8] R. Momparler,et al. Effects of 5-aza-2'-deoxycytidine on survival and cell cycle progression of L1210 leukemia cells. , 1986, Leukemia research.
[9] E. McFadden,et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.